The Invokana CANVAS study, mandated by the FDA as part of post-marketing requirements and sponsored by manufacturer Janssen Pharmaceuticals, has had mixed results. On one hand, patients who were treated with Invokana (canagliflozin) experienced significantly lower rates of stroke and heart attacks. On the other hand, the risk of lower limb amputations was double those of patients who took a placebo.
For some time, there has been concern over sodium-glucose transport-2 (SGLT-2) inhibitors such as Invokana (canagliflozin), Farxiga (dapagliflozin) and Jardiance (empagliflozin), and whether these prescription medications increase a patient's risk of certain types of cancer. A new study published this month in the journal Diabetology shows that SGLT-2 inhibitors do not necessarily increase a patient's cancer risk.
In the wake of an FDA advisory on the link between Invokana (canagliflozin) and an elevated risk of lower limb amputations, a number of physicians and health care providers in California have stopped prescribing the diabetic drug to their patients.
In May, Drug Safety News published a story about the association between treatment with the diabetic drug Invokana (canagliflozin) and an increased risk of lower limb amputation. Despite strong evidence from a number of clinical studies in the U.S.
This week, Johnson & Johnson was celebrating results from its CANVAS and CANVAS-R studies, showing that its diabetic drug Invokana (canagliflozin) reduced the risk of heart attacks and strokes by 14%. Those results were presented on Monday at the 77th annual meeting of the American Diabetes Association. That compared very favorably with rival prescription medication Jardiance (empagliflozin), a product of Eli Lilly and Company.
When there is a sizable number of lawsuits against a company with similar causes of action, there is usually a movement to combine all of the trials so they are heard before one judge. It's a way to economize on judicial resources and eliminate duplicate efforts when it comes to gathering evidence, filing motions and other pretrial proceedings. This is what is currently happening in lawsuits against Janssen Pharmaceuticals regarding the Type 2 diabetic prescription drug, Invokana (canagliflozin).
It took far too long, but as of this past August, the warning label for the diabetic drug Invokana (canagliflozin) was finally updated to include the risk of ketoacidosis. It was also updated for a rival drug, Farxiga (dapaglifozin), as well as Jardiance (empagliflozin). All three of these medications are part of the gliflozin class, which are designed to prevent the kidneys from reabsorbing blood sugar, allowing it to be passed in the urine.
While the diabetic medication Invokana (canagliflozin) has been implicated in the development ketoacidosis in patients, it is not the only prescription drug in its class to have such a serious side effect. It was well over a year ago (May 2015, to be exact) that the Food and Drug Administration issued a statement on receiving numerous reports of how the entire class of gliflozin drugs was causing dangerous ketoacidosis. In fact, during the two years prior to issuing that statement, the FDA had received in excess of 100 reports of serious kidney damage.
Considering our government is bought and paid for by Big Pharma, it’s only fitting that Janssen Pharmaceuticals has used the Beltway’s time-honored “Friday news dump” to inform the public that its blockbuster diabetes medication, Invokana, causes kidney injuries when it quietly updated Invokana’s warning label on Friday, May 20, 2016. Invokana is in a class of medications called sodium glucose cotransporter 2 (SGLT2) inhibitors which are intended to treat high blood sugar in type 2 diabetics.